FDA Approves Nipocalimab for Adult and Pediatric Myasthenia Gravis

The FDA approved nipocalimab (Imaavy) injection to treat adults and children ages 12 and older with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle-specific kinase (MuSK) antibody positive, Johnson & Johnson announced Wednesday. Nipocalimab is designed to block the immunoglobulin G (IgG) binding site on the neonatal Fc receptor (FcRn) to reduce […]

Topical Gel Soothes Skin Rash for CRC Patients on EGFR Inhibitors

The use of an investigational topical BRAF-inhibiting gel appeared to be effective in treating acneiform rash in patients with advanced colorectal cancer who were treated with an epidermal growth factor receptor (EGFR)-targeted drug, a randomized phase II trial showed. The 39 patients randomly assigned to receive a high-dose 0.1% formulation of LUT014 gel were twice […]

Women Happier With Vaginal Tape Slings for Stress Urinary Incontinence

Women with stress urinary incontinence were more satisfied with outcomes when treated with a tension-free vaginal tape (TVT) procedure rather than bulking therapy with transurethral polyacrylamide hydrogel injection. However, a high percentage of women in both groups appeared to be satisfied with outcomes over the long-term. More women were objectively cured with TVT, but most […]

Buprenorphine for OUD Tied to Better Outcomes for Mother and Baby

Buprenorphine treatment was linked with better outcomes for mother and infant, according to a study of pregnant individuals with opioid use disorder (OUD). Among 14,463 maternal-infant dyads, there was a statistically significant lower rate of adverse pregnancy outcomes among those who were treated with buprenorphine compared to those who did not receive treatment (25.4% vs […]

Unprecedented Response Rates in Non-Responsive, Non-Muscle Invasive Bladder Cancer

LAS VEGAS — Patients with high-risk, treatment-unresponsive non-muscle invasive bladder cancer (NMIBC) had an unprecedented response rate and disease-free survival (DFS) with an investigational intravesical treatment system, data from an ongoing trial showed. Complete responses (CR) occurred in 82.4% of 85 patients treated with TAR-200, a system that delivers gemcitabine directly into the bladder. The […]